Semaglutide 5mg

Semaglutide 5mg

Manufacturer: Euro-Pharmacies
Package: 5 mg/vial
Common Names: Semaglutide, Semaglutide 5mg, Semaglutide 5 mg, Semaglutide Peptide, GLP-1 Receptor Agonist, GLP-1 Analog, Semaglutide Vial

Info: (EP) Semaglutide 5mg from Euro-Pharmacies contains semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the activity of endogenous GLP-1. Semaglutide influences glucose-dependent insulin secretion, glucagon regulation, gastric emptying, and appetite-related signaling. It has been extensively studied for the management of type 2 diabetes and chronic weight management.

Effects

Glucose Regulation: Semaglutide enhances glucose-dependent insulin secretion and reduces inappropriate glucagon release, supporting improved glycemic control.

Appetite and Weight Management: Semaglutide acts on areas of the central nervous system involved in appetite regulation and may reduce hunger and food intake, contributing to weight reduction when used as part of an appropriate treatment program.

Side Effects

Potential adverse effects associated with semaglutide commonly include nausea, vomiting, diarrhea, constipation, abdominal discomfort, decreased appetite, and other gastrointestinal symptoms. These effects may be more noticeable during dose escalation.

More serious risks may include pancreatitis, gallbladder-related disorders, dehydration associated with gastrointestinal symptoms, hypoglycemia when combined with certain glucose-lowering medicines, and potential worsening of diabetic retinopathy in susceptible individuals.

Dosage Range and Duration of Use

For chronic weight management or type 2 diabetes, subcutaneous semaglutide is initiated at 0.25 mg once weekly for the first 4 weeks, titrating every 4 weeks through 0.5 mg, 1.0 mg, and 1.7 mg up to the target maintenance dose of 2.4 mg once weekly (or up to 2.0 mg for diabetes control). Oral formulations typically start at 3 mg once daily for 30 days, increasing to 7 mg and up to 14 mg daily. Treatment is intended for long-term continuous use under medical supervision. Semaglutide is a long-acting compound with an elimination half-life of approximately one week, allowing once-weekly administration in approved injectable formulations. Dosage adjustments should be made only according to the applicable prescribing information and healthcare professional guidance.  

Combination with Other Drugs

Semaglutide may interact with other medicines that affect blood glucose levels, particularly insulin and insulin secretagogues, potentially increasing the risk of hypoglycemia. Because semaglutide can delay gastric emptying, it may also influence the absorption of certain orally administered medicines. Any combination with other prescription medicines should be reviewed by a healthcare professional before use.